Preferred Label : Anti-CD47 Monoclonal Antibody IMC-002;
NCIt definition : A human immunoglobulin G4 (IgG4) monoclonal antibody targeting leukocyte surface antigen
CD47, with potential immune checkpoint inhibitory and antineoplastic activities. Upon
administration, anti-CD47 monoclonal antibody IMC-002 targets and binds to CD47 expressed
on tumor cells, blocking the interaction of CD47 with signal regulatory protein alpha
(SIRPa) expressed on phagocytic cells. This prevents CD47/SIRPa-mediated signaling
and abrogates the CD47/SIRPa-mediated inhibition of macrophage activation and phagocytosis
of cancer cells. This induces pro-phagocytic signaling mediated by the binding of
calreticulin (CRT), which is specifically expressed on the surface of tumor cells,
to low-density lipoprotein (LDL) receptor-related protein-1 (LRP-1), which is expressed
on macrophages, and results in macrophage activation and the specific phagocytosis
of tumor cells. CD47, also called integrin-associated protein (IAP), is a tumor-associated
antigen (TAA) expressed on normal, healthy hematopoietic stem cells (HSCs) and overexpressed
on the surface of a variety of cancer cells. Expression of CD47, and its interaction
with SIRPa, leads to the inhibition of macrophage activation and protects cancer cells
from phagocytosis, thereby allowing cancer cells to proliferate. IMC-002 does not
bind to red blood cells (RBCs). This may prevent adverse effects such as anemia that
can result from the blockade of CD47 expressed on RBCs.;
Molecule name : IMC-002; IMC 002;
NCI Metathesaurus CUI : CL1407837;
Origin ID : C174192;
UMLS CUI : C5418072;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
